OPA1 and Leigh syndrome: We found that DNJ targeted nuclear-encoded OPA1 to function as a mitochondrial rescue agent, showing the therapeutic potential of our mitochondrial hypertrophic cardiomyopathy and even other mitochondrial diseases, such as hearing loss, mitochondrial myopathy, or Leigh syndrome.